Response to Levrier re: Human Germline and Heritable Genome Editing: The Global Policy Landscape
By Marcy Darnovsky, Katie Hasson, and Timothy M. Krahn,
The CRISPR Journal
| 02. 19. 2021
In response to: https://www.liebertpub.com/doi/10.1089/crispr.2021.29121.gle
Levrier apparently misunderstands the nature of our project published in The CRISPR Journal in October 2020.1 We identified and reviewed policy documents relevant to human germline and heritable genome editing research in 96 countries. We did not speculate about arguments that might lead legislatures or courts to revise existing policies or adjudicate prospective cases, nor did we attempt to examine each policy in its national or international context. Rather, based on close and careful readings of the identified texts, we categorized countries according to the current permissibility or impermissibility of germline and heritable genome editing. Then, we counted.
We welcome corrections and additions to the data we have compiled, which we plan to keep updated at https://tinyurl.com/HumanGenomeEditingPolicies. Unfortunately, Levrier does not provide appropriate documentation for his challenge to our categorizations regarding human germline and heritable genome editing research in three countries (France, Mexico, and Japan). Instead, he points to a report, unspecified “debates” in the French parliament, and comments on social media. We sometimes used such sources to identify relevant policy documents, but did...
Related Articles
Artificial Intelligence (AI) has been a major focus of news recently, as it should have been, under the appropriately ridiculous name of Hugging Face, “a leading collaboration platform and community hub for machine learning, artificial intelligence, and data science.” In July, Hugging Face was hacked. The platform itself responded:
Earlier this week, we detected and responded to an intrusion into part of our production infrastructure. This one was different from anything we had handled before in one important way...
By Miryam Naddaf, Nature | 09.21.2026
A wave of epigenetic therapies is offering hope as ways to cure chronic hepatitis B — a lingering liver infection that is caused by the hepatitis B virus (HBV) and affects more than 250 million people around the world. Currently...
By Karen Weintraub, Endpoints News | 09.16.2026
To better understand certain neuropsychiatric disorders, researchers at Stanford University have bred rodents that lack a cortex and hippocampus and then replaced those missing brain cells with human ones.
The altered mice, a scientific first, provided insights that would not...
By Ryan Cross, Endpoints News | 09.02.2026
The deaths of two children who received CRISPR therapies in China have rattled scientists who work on similar genetic medicines in the US, adding new fuel to a yearslong debate about the danger of the gene therapy field’s most-used delivery...